Molecule Details
| InChIKey | OESBDSFYJMDRJY-BAYCTPFLSA-N |
|---|---|
| Compound Name | Tecadenoson |
| Canonical SMILES | OC[C@H]1O[C@@H](n2cnc3c(N[C@@H]4CCOC4)ncnc32)[C@H](O)[C@@H]1O |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 7.47 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB04954 |
|---|---|
| Drug Name | Tecadenoson |
| CAS Number | 204512-90-3 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. It is being developed by CV Therapeutics, Inc. |
Categories: Heterocyclic Compounds, Fused-Ring Neurotransmitter Agents Nucleic Acids, Nucleotides, and Nucleosides Nucleosides Purine Nucleosides Purinergic Agents Purinergic Agonists Purinergic P1 Receptor Agonists Purines Ribonucleosides
Cross-references: BindingDB: 50224766 CHEMBL392149 ChemSpider: 139685 PubChem:158795 PubChem:175426918
Target Activities (2)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P30542 | ADORA1 | Adenosine receptor A1 | agonist | targets |